Erin Lantz Biography and Net Worth

CRO of aTyr Pharma

Erin brings years of experience building and scaling businesses at leading real estate and financial services organizations, including Zillow Group and BofA. She serves on the boards of Blend and Meritage. Erin holds a BA in Political Science, Philosophy, and Economics from the University of Pennsylvania and an MBA from Harvard Business School.

What is Erin N. Lantz's net worth?: The estimated net worth of Erin N. Lantz is at least $3.36 million as of January 30th, 2026. Lantz owns 253,904 shares of aTyr Pharma stock worth more than $3,361,689 as of March 10th. This net worth approximation does not reflect any other assets that Lantz may own. Learn More about Erin N. Lantz's net worth.
How do I contact Erin N. Lantz?: The corporate mailing address for Lantz and other aTyr Pharma executives is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. aTyr Pharma can also be reached via phone at (858) 731-8389 and via email at [email protected]. Learn More on Erin N. Lantz's contact information.
Has Erin N. Lantz been buying or selling shares of aTyr Pharma?: During the last ninety days, Erin N. Lantz has sold $2,905,411.22 in aTyr Pharma stock. Most recently, Erin N. Lantz sold 162,677 shares of the business's stock in a transaction on Friday, January 30th. The shares were sold at an average price of $17.86, for a transaction totalling $2,905,411.22. Following the completion of the sale, the executive now directly owns 253,904 shares of the company's stock, valued at $4,534,725.44. Learn More on Erin N. Lantz's trading history.
Who are aTyr Pharma's active insiders?: aTyr Pharma's insider roster includes Jill Broadfoot (CFO), John Clarke (Director), Brandt Kucharski (CAO), Erin Lantz (CRO), Paul Schimmel (Director), and Sanjay Shukla (CEO). Learn More on aTyr Pharma's active insiders.
Are insiders buying or selling shares of aTyr Pharma?: In the last twelve months, aTyr Pharma insiders bought shares 3 times. They purchased a total of 526,313 shares worth more than $9,999,947.00. In the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 2,020,413 shares worth more than $38,188,227.30. The most recent insider tranaction occured on January, 30th when Director William J Wheeler bought 260,525 shares worth more than $4,949,975.00. Insiders at aTyr Pharma own 3.7% of the company. Learn More about insider trades at aTyr Pharma.
Information on this page was last updated on 1/30/2026.

Erin N. Lantz Insider Trading History at aTyr Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/30/2026	Sell	162,677	$17.86	$2,905,411.22	253,904

Erin N. Lantz Buying and Selling Activity at aTyr Pharma

aTyr Pharma Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Today's Range

Now: $12.79

$12.44

$13.58

50 Day Range

MA: $1.76

$1.57

$2.07

2 Week Range

Now: $12.79

$1.08

$2.45

Volume

561,679 shs

Average Volume

514,103 shs

Market Capitalization

$882.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19